

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)Applicant(s): **Lewis et al**

Docket No.

3618/1

Serial No.

10/634,199


Filing Date

August 5, 2003

Examiner

Unknown

Group Art Unit

UnknownInvention: **FORMULATION OF MODIFIED ANTIBODIES AND METHOD OF MAKING THE SAME**I hereby certify that this **IDS Form 1449, IDS Response, IDS References, Postcard**
(Identify type of correspondence)is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on **10/6/03**
(Date)**Michelle R. Becker**

(Typed or Printed Name of Person Mailing Correspondence)


(Signature of Person Mailing Correspondence)**Note: Each paper must have its own certificate of mailing.**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of
Lewis, et al.


Serial No. 10/634,199

Filed: August 5, 2003

)
) Attorney Docket No. 3618/1

)
) Group Art Unit: Unknown

)
) Examiner: Unknown



FORMULATIONS OF MODIFIED ANTIBODIES AND METHODS OF MAKING
THE SAME

October 6, 2003

Commissioner of Patents
PO Box 1450
Alexandria, VA 22313


SIR:

INFORMATION DISCLOSURE STATEMENT


In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit herewith various documents cited on the attached Form PTO 1449. Applicants respectfully request that the Examiner consider and enter all the documents cited on the enclosed Form PTO 1449 into the file of the above-identified application. Applicants also request an indication of the same by return of the Form PTO 1449 being initialed and dated by the Examiner.

No additional fees are believed due to ensure consideration of the attached documents by the Examiner. However, if any additional fees are required or an overpayment of fees made, the Commissioner is hereby authorized to debit or credit our Deposit Account No. 19-1025, as necessary.

Respectfully submitted,


James M. Warner, Reg. No. 45,199
Attorney for Applicants
(314) 274-3642 (St. Louis)

Pharmacia Corporation
Corporate Patent Department
P.O. Box 1027
Chesterfield, MO 63006



FORM PTO-1449

U.S. DEPARTMENT OF
COMMERCE, PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET
NO.: 3618/1APPLICATION NO.:
10/634,199

INVENTOR: Lewis, et al.

Filed: 08/05/2003

Group:

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	4,301,144					
	4,496,689					
	4,640,835					
	4,670,417					
	4,791,192					
	4,816,567					
	5,643,575					
	5,654,407					
	5,795,697					
	5,919,455					
	5,932,462					
	6,090,923					
	6,113,906					
	6,248,471					
	6,267,958					
	6,528,562					


FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	1	WO 01/94585						
	2	WO 97/04801						
	3	EP 788515						

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609.
Draw line through citation if not in conformance and not considered. Include copy of this form with
next communication to applicant.



(Form PTO-1449)

Sheet 2 of 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: 3618/1	APPLICATION NO.: 10/634,199
	INVENTOR: Lewis, et al.	
	Filed: 8/05/03	Group:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
	4	Meager et al; Hybridoma; 6: 305-311; 1987
	5	Fendley et al; Hybridoma; 6: 359-370; 1987
	6	Shiamoto et al; Immunology Letters; 17: 311-318; 1988
	7	Rankin et al; British J. Rheumatology; 34 ; 334-342; 1995
	8	Pikal, M.; Biopharm; 3(9); 26-30; 1990
	9	Arkawa et al; Pharm Res; 8(3); 285-291; 1991
	10	Stratton, Lewis et al; J of Pharm Sci; 90(12); 2141-2148; Dec. 2001
	11	Ishi, Yoshiharu et al; Boiphys J.; 50; 75-80; July 1986
	12	Kohler et al; Nature; 256: 495; 1975
	13	Clackson et al; Nature 352: 624-628; 1991
	14	Marks et al; J Mol. Biol.; 222: 581-597; 1991
	15	Morrison et al; Proc Natl Acad Sci USA; 81: 6851-6855; 1984
	16	Chothia Lesk; J Mol Biol; 196; 901-917; 1987
	17	Jones et al; Nature; 321; 522-525; 1986
	18	Reichmann et al; Nature: 332; 323-329; 1988
	19	Piesta; Curr. Op. Struct Biol.; 2: 593-596; 1992

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

(Form PTO-1449)



Sheet 1 of 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: 3618/1	APPLICATION NO.: 10/634,199
	INVENTOR: Lewis, et al.	
	Filed: 08/05/2003	Group:

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	4,301,144					
	4,496,689					
	4,640,835					
	4,670,417					
	4,791,192					
	4,816,567					
	5,643,575					
	5,654,407					
	5,795,697					
	5,919,455					
	5,932,462					
	6,090,923					
	6,113,906					
	6,248,471					
	6,267,958					
	6,528,562					

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	1	WO 01/94585						
	2	WO 97/04801						
	3	EP 788515						

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



(Form PTO-1449)

Sheet 2 of 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: 3618/1	APPLICATION NO.: 10/634,199
	INVENTOR: Lewis, et al.	
	Filed: 8/05/03	Group:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
	4	Meager et al; Hybridoma; 6: 305-311; 1987
	5	Fendley et al; Hybridoma; 6: 359-370; 1987
	6	Shiammoto et al; Immunology Letters; 17: 311-318; 1988
	7	Rankin et al; British J. Rheumatology; 34 ; 334-342; 1995
	8	Pikal, M.; Biopharm; 3(9); 26-30; 1990
	9	Arkawa et al; Pharm Res; 8(3); 285-291; 1991
	10	Stratton, Lewis et al; J of Pharm Sci; 90(12); 2141-2148; Dec. 2001
	11	Ishi, Yoshiharu et al; Boiphys J.; 50; 75-80; July 1986
	12	Kohler et al; Nature; 256: 495; 1975
	13	Clackson et al; Nature 352: 624-628; 1991
	14	Marks et al; J Mol. Biol.; 222: 581-597; 1991
	15	Morrison et al; Proc Natl Acad Sci USA; 81: 6851-6855; 1984
	16	Chothia Lesk; J Mol Biol; 196; 901-917; 1987
	17	Jones et al; Nature; 321; 522-525; 1986
	18	Reichmann et al; Nature: 332; 323-329; 1988
	19	Piesta; Curr. Op. Struct Biol.; 2: 593-596; 1992

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

(Form PTO-1449)